Therapy of entamebiasis

Area of Science:

• Medical Parasitology
• Infectious Diseases
• Pharmacology

Background:

• Entamebiasis, if untreated, can be fatal, necessitating effective therapeutic strategies.
• Recent standardization of isoenzyme electrophoresis allows differentiation of pathogenic and non-pathogenic Entamoeba histolytica strains.
• Non-pathogenic strains do not require treatment, simplifying therapeutic decisions.

Purpose of the Study:

• To outline current therapeutic approaches for entamebiasis based on disease form and causative amebae.
• To highlight key pharmacological agents and their indications for intestinal and extraintestinal amebiasis.

Main Methods:

• Classification of amebiasis into intestinal and extraintestinal forms.
• Identification of pathogenic strains using isoenzyme electrophoresis (zymodemes).
• Review of established drug treatments and their efficacy.

Main Results:

• Diloxanide furoate is the primary treatment for asymptomatic luminal infections.
• Metronidazole and related 5-nitroimidazoles are crucial for symptomatic intestinal and extraintestinal amebiasis, including liver abscesses.
• Combination therapy, often including chloroquine for extraintestinal disease and a follow-up with diloxanide furoate, ensures parasite clearance.

Conclusions:

• Accurate differentiation of Entamoeba strains is key to targeted entamebiasis therapy.
• Pharmacological treatment varies based on disease manifestation (intestinal vs. extraintestinal).
• A multi-drug approach, including luminal and tissue-penetrating agents, is often necessary for successful eradication.